Of these, three patients had NTRK1/2/3 gene fusion (none with CCA), and all three manifested a response, suggesting promise in using entrectinib in the management of solid malignancies with NTRK1/2/3 fusion. This evidence concerns the gene NTRK1 and cholangiocarcinoma.